Moreover, the SURPASS trial program has demonstrated that the GLP-1/GIP dual receptor agonist Tirzepatide provides superior glycemic control and weight loss compared to selective GLP-1 receptor agonists like Semaglutide (10, 11)
A direct effect of tirzepatide at the GIPR in adipose tissue surrounding and within the kidney, such as perirenal fat and intrarenal fat, may favorably affect inflammation known to contribute to kidney dysfunction
If weight loss has stalled or side effects are too strong, adjustments are made
When your PCP declines to prescribe weight-loss medication, the first step is to understand why
Weight loss peptides and fertility benefits refer to specific peptides that may aid weight reduction while supporting reproductive health
By continuing to browse, you accept our use of cookies